According to a new report by UnivDatos, the Antibiotic Resistance Market is expected to reach ~USD 13.32 billion in 2032 by growing at a CAGR of ~5.4%. Antimicrobial resistance is a very sensitive and evolving threat within the healthcare market and is indicated by the emergence of multidrug-resistant organisms, to which standard antibiotics are ineffective. These increased rates have made treatment failures become more common, lengths of stay rise, and costs skyrocket, all of which have created the need for new approaches that will address the issues. Industry is keen on investing in the development of new antibiotics and other therapies, and in diagnostics tools because of the high threat level of resistant infections in patients. Other opportunities are related to the geographical areas of diagnostics advances and international partnerships that call for an active strategy to fight antibiotic resistance. In conclusion, there is great potential within the market as key players are aware that increased awareness for practical solutions to reducing the burden of antibiotic resistance on the population is needed.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/antibiotic-resistance-market?popup=report-enquiry

KEY GROWTH DRIVERS:

Antibiotic resistance market can be treated as an emerging market since it is associated with a new threat to the world’s health – antimicrobial resistance. This is even more so since many of the modern antibiotics cannot fulfill this promise because multi-drug-resistant organisms have developed ways in which they can overcome the effects of these drugs. The main catalysts for the market are the increasing rates of infections, including those acquired in hospitals, and improved awareness of healthcare workers and the population about the effects of antimicrobial resistance. National authorities and institutions invest in the early stages of research and development, and the progress of diagnostic methods, vaccines, and management strategies.

· In March 2024, Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for EMBLAVEO (aztreonam-avibactam) in the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

· In December 2023, Orchid Pharma announced a merger with Dhanuka Labs, the promoter of the company, in a significant move towards achieving consolidation and fueling the next level of growth.

The report suggests that the Increasing Incidence of Infections is a significant factor driving the growth of the antibiotic resistance market in the coming years. Healthcare-associated infections (HAIs) are increasing, and these infections are major contributing factors towards antimicrobial resistance (AMR) hence driving the AMR market. Since both hospitals and clinics have increased instances of HAIs, the need for quality antimicrobials surfaces. Methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Gram-negative bacteria are emerging as significant infectious threats to patients and healthcare organizations. These pathogens can result in the protraction of hospital stays, elevated rates of medical spending, and, subsequently, the mortality rates; all of them reflecting the unmet therapeutic needs. Consequently, the need for advanced antibiotics and non-traditional approaches to treating infections increases as the population ages and the incidence of chronic diseases grows. Moreover, increased knowledge regarding the repercussions of AMR among healthcare providers played a role in the enhancement of the role of infection prevention and control. This includes embracing new technology and approaches that will enhance efficient infection control hence propelling the demand for new molecules as well as other related solutions. As such, a higher rate of infections together with the rising threat of resistant strains is driving markets for AMR by researching, investing, and developing better treatments for patients.

Click here to view the Report Description & TOC : https://univdatos.com/reports/antibiotic-resistance-market

Blood Stream InfectionsSegmentGaining Maximum Traction in the Market

The constant increase in the antibiotic resistance bloodstream infection (BSI) segment is expected due to the constantly increasing number of multidrug-resistant organisms, including Gram-negative bacteria such as Klebsiella pneumoniae and Escherichia coli. Thus, with the continuous report of higher levels of resistance to traditional antibiotics among such pathogens, there is a growing need for treatment. Moreover, bloodstream infection is life-threatening and complicated and results in high mortality among hospitalized patients and immunocompromised persons. This has prompted pharmaceutical firms to try and come up with new antibiotics, with different actions and a combination of therapies that work well against resistant strains of bacteria.

Conclusion

The global antibiotic resistance market is rapidly growing, with advancements in the healthcare industry leading to improved outcomes. The global market is expected to increase as new innovative products are developed in the coming years. Thus, the international antibiotic resistance market represents a significant opportunity for companies to make strategic alliances to launch a diversity of products for the global population. With continued development, more products will likely become available, improving consumer outcomes.

Contact Us:

UnivDatos

Contact Number - +1 978 733 0253

Email - contact@univdatos.com

Website - https://univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos/